Related references
Note: Only part of the references are listed.Impact of Age and Primary Disease Site on Outcome in Women With Low-Grade Serous Carcinoma of the Ovary or Peritoneum: Results of a Large Single-Institution Registry of a Rare Tumor
David M. Gershenson et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Genomic Classification of Serous Ovarian Cancer with Adjacent Borderline Differentiates RAS Pathway and TP53-Mutant Tumors and Identifies NRAS as an Oncogenic Driver
Catherine Emmanuel et al.
CLINICAL CANCER RESEARCH (2014)
Association of KRAS and EGFR mutations with survival in patients with advanced lung adenocarcinomas
Melissa L. Johnson et al.
CANCER (2013)
BRAF Mutation is associated with early stage disease and improved outcome in patients with low-grade serous ovarian cancer
Rachel N. Grisham et al.
CANCER (2013)
KRAS (but not BRAF) mutations in ovarian serous borderline tumour are associated with recurrent low-grade serous carcinoma
Yvonne T. Tsang et al.
JOURNAL OF PATHOLOGY (2013)
Selumetinib in women with recurrent low-grade serous carcinoma of the ovary or peritoneum: an open-label, single-arm, phase 2 study
John Farley et al.
LANCET ONCOLOGY (2013)
Low-grade serous primary peritoneal carcinoma
Kathleen M. Schmeler et al.
GYNECOLOGIC ONCOLOGY (2011)
BRAF Mutation Is Rare in Advanced-Stage Low-Grade Ovarian Serous Carcinomas
Kwong-Kwok Wong et al.
AMERICAN JOURNAL OF PATHOLOGY (2010)
Wilms tumor 1 (WT1) regulates KRAS-driven oncogenesis and senescence in mouse and human models
Silvestre Vicent et al.
JOURNAL OF CLINICAL INVESTIGATION (2010)
SENESCENCE Senescence in tumours: evidence from mice and humans
Manuel Collado et al.
NATURE REVIEWS CANCER (2010)
Prognostic and predictive value of common mutations for treatment response and survival in patients with metastatic colorectal cancer
J. Souglakos et al.
BRITISH JOURNAL OF CANCER (2009)
Oncogenic Braf Induces Melanocyte Senescence and Melanoma in Mice
Nathalie Dhomen et al.
CANCER CELL (2009)
Comparison of the clinical behavior of newly diagnosed stages II-IV low-grade serous carcinoma of the ovary with that of serous ovarian tumors of low malignant potential that recur as low-grade serous carcinoma
Hyun S. Shvartsman et al.
GYNECOLOGIC ONCOLOGY (2007)
Senescence and tumour clearance is triggered by p53 restoration in murine liver carcinomas
Wen Xue et al.
NATURE (2007)
Clinical behavior of stage II-IV low-grade serous carcinoma of the ovary
David M. Gershenson et al.
OBSTETRICS AND GYNECOLOGY (2006)
Grading ovarian serous carcinoma using a two-tier system
A Malpica et al.
AMERICAN JOURNAL OF SURGICAL PATHOLOGY (2004)
Mutations in BRAF and KRAS characterize the development of low-grade ovarian serous carcinoma
G Singer et al.
JOURNAL OF THE NATIONAL CANCER INSTITUTE (2003)
Response and survival in patients with progressive or recurrent serous ovarian tumors of low malignant potential
MA Crispens et al.
OBSTETRICS AND GYNECOLOGY (2002)
Kirsten ras mutations in patients with colorectal cancer:: the 'RASCAL II' study
HJN Andreyev et al.
BRITISH JOURNAL OF CANCER (2001)
Share Paper
